Comparative Pharmacology
Head-to-head clinical analysis: FOCALIN versus FOCALIN XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOCALIN versus FOCALIN XR.
FOCALIN vs FOCALIN XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexmethylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their synaptic concentrations. The d-threo enantiomer of methylphenidate is responsible for the therapeutic activity.
Focalin XR (dexmethylphenidate) is a central nervous system stimulant. It blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft. The d-threo enantiomer is pharmacologically active.
Initial 2.5-5 mg orally twice daily, increase by 2.5-10 mg/day weekly; max 20 mg twice daily.
Initial 20 mg orally once daily; may increase in 10-20 mg increments at weekly intervals; maximum 60 mg/day.
None Documented
None Documented
2-3 hours in children and adults; 4-5 hours in adolescents (due to slower metabolism). Clinical context: t1/2 supports twice-daily dosing (immediate-release) for continuous therapeutic effect
Terminal half-life: 2-3 hours for immediate-release; 6-8 hours for extended-release (FOCALIN XR)
Renal: 80% (approximately 50% as unchanged drug, 30% as metabolites); Fecal: negligible
Renal (approximately 90% as unchanged drug and metabolites)
Category C
Category C
CNS Stimulant
CNS Stimulant